Skip to main content
Erschienen in: Inflammopharmacology 2/2024

08.02.2024 | Review

A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis

verfasst von: Mohammad Ali Nilforoushzadeh, Nazila Heidari, Yekta Ghane, Amirhossein Heidari, Arman Hajikarim-Hamedani, SeyedAyin Hosseini, Fariba Jaffary, Minou Najar Nobari, Pegah Tavakolzadeh, Niloufar Najar Nobari

Erschienen in: Inflammopharmacology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Prurigo nodularis (PN) is a neuroimmunological skin disease. Severe itching is the most challenging symptom which affects patients’ quality of life. T helper 2-derived cytokines, such as interleukin-31 and oncostatin M (OSM), play a crucial role in PN pathogenesis. Nemolizumab and vixarelimab are two biologics acting as IL-31 inhibitors. Vixarelimab also suppresses the OSM activity. This systematic review evaluates the efficacy and safety of nemolizumab and vixarelimab in PN management.

Methods

A systematic search was conducted in PubMed/Medline, Ovid Embase, and Web of Science up to September 17th, 2023. Clinical trials and cohort studies published in English were included.

Results

Among a total of 96 relevant records, five were included. The results of four studies with 452 patients using nemolizumab showed that a significantly higher percentage of patients treated with nemolizumab demonstrated a reduction in peak pruritus numerical rating scale (PP-NRS) and investigator’s global assessment along with improved sleep disturbance (SD) and quality of life than the placebo group. Moreover, one study administered vixarelimab to 49 PN patients, and their finding illustrated a higher rate of subjects who received vixarelimab experienced ≥ 4-point diminution in worst itch NRS, visual analog scale, healing of representative lesions, and SD quality compared to the placebo group.

Conclusions

IL-31 inhibitors suggest distinct advantages in improving pruritus, sleep quality, and overall quality of life in subjects with moderate-to-severe PN. Further clinical studies are recommended to compare the effectiveness of these biologics to other therapeutic choices.
Literatur
Zurück zum Zitat L. National Heart aBI. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. 2014. L. National Heart aBI. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. 2014.
Zurück zum Zitat National Heart L, and Blood Institute. Quality Assessment of Clinical trials. 2014. National Heart L, and Blood Institute. Quality Assessment of Clinical trials. 2014.
Zurück zum Zitat Tsoi L, Fogel P, Xing X, Patrick MT, Billi AC, Berthier CC et al (2021) Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Investig Dermatol 141(9):B27CrossRef Tsoi L, Fogel P, Xing X, Patrick MT, Billi AC, Berthier CC et al (2021) Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Investig Dermatol 141(9):B27CrossRef
Metadaten
Titel
A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis
verfasst von
Mohammad Ali Nilforoushzadeh
Nazila Heidari
Yekta Ghane
Amirhossein Heidari
Arman Hajikarim-Hamedani
SeyedAyin Hosseini
Fariba Jaffary
Minou Najar Nobari
Pegah Tavakolzadeh
Niloufar Najar Nobari
Publikationsdatum
08.02.2024
Verlag
Springer International Publishing
Erschienen in
Inflammopharmacology / Ausgabe 2/2024
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-024-01436-9

Weitere Artikel der Ausgabe 2/2024

Inflammopharmacology 2/2024 Zur Ausgabe